Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis

被引:2
|
作者
Phillips, Andrew N. [1 ,12 ]
Bansi-Matharu, Loveleen [1 ]
Shahmanesh, Maryam [1 ,2 ]
Hargreaves, James R. [3 ]
Smith, Jennifer [1 ]
Revill, Paul [4 ]
Sibanda, Euphemia [5 ,6 ]
Ehrenkranz, Peter [7 ]
Sikwese, Kenly [8 ]
Rodger, Alison [1 ]
Lundgren, Jens [9 ]
Gilks, Charles F. [10 ]
Godfrey, Catherine [11 ]
Cowan, Frances [5 ,6 ]
Cambiano, Valentina [1 ]
机构
[1] UCL, Inst Global Hlth, London, England
[2] Africa Hlth Res Inst, Kwa Zulu, South Africa
[3] London Sch Hyg &Trop Med, London, England
[4] Univ York, Ctr Hlth Econ, York, England
[5] CeSHHAR Zimbabwe, Harare, Zimbabwe
[6] Univ Liverpool Liverpool Sch Trop Med, Liverpool, England
[7] Bill & Melinda Gates Fdn, Seattle, WA USA
[8] Akros, Lusaka, Zambia
[9] Univ Copenhagen, Rigshosp, Copenhagen, Denmark
[10] Univ Queensland, Brisbane, Qld, Australia
[11] Off Global AIDS Coordinator, Dept State, Washington, DC USA
[12] UCL, Inst Global Hlth, London NW3 2PF, England
来源
LANCET GLOBAL HEALTH | 2023年 / 11卷 / 10期
关键词
POSTEXPOSURE PROPHYLAXIS; WOMEN;
D O I
10.1016/S2214-109X(23)00383-2
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Post-exposure prophylaxis (PEP) offers protection from HIV after condomless sex, but is not widely available in a timely manner in east, central, southern, and west Africa. To inform the potential pilot implementation of such an approach, we modelled the effect and cost-effectiveness of making PEP consisting of tenofovir, lamivudine, and dolutegravir (TLD) freely and locally available in communities without prescription, with the aim of enabling PEP use within 24 h of condomless sex. Free community availability of TLD (referred to as community TLD) might also result in some use of TLD as pre-exposure prophylaxis (PrEP) and as antiretroviral therapy for people living with HIV. Methods Using an existing individual-based model (HIV Synthesis), we explicitly modelled the potential positive and negative effects of community TLD. Through the sampling of parameter values we created 1000 setting-scenarios, reflecting the uncertainty in assumptions and a range of settings similar to those seen in east, central, southern, and west Africa (with a median HIV prevalence of 14 center dot 8% in women and 8 center dot 1% in men). For each setting scenario, we considered the effects of community TLD. TLD PEP was assumed to have at least 90% efficacy in preventing HIV infection after condomless sex with a person living with HIV. Findings The modelled effects of community TLD availability based on an assumed high uptake of TLD resulted in a mean reduction in incidence of 31% (90% range over setting scenarios, 6% increase to 57% decrease) over 20 years, with an HIV incidence reduction over 50 years in 91% of the 1000 setting scenarios, deaths averted in 55% of scenarios, reduction in costs in 92% of scenarios, and disability-adjusted life-years averted in 64% of scenarios with community TLD. Community TLD was cost-effective in 90% of setting scenarios and cost-saving (with disability-adjusted life-years averted) in 58% of scenarios. When only examining setting scenarios in which there was lower uptake of community TLD, community TLD is cost-effective in 92% of setting scenarios. Interpretation The introduction of community TLD, enabling greater PEP access, is a promising approach to consider further in pilot implementation projects.
引用
收藏
页码:E1648 / E1657
页数:10
相关论文
共 50 条
  • [1] The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
    Aprilianti, Santi
    Utami, Auliasari M.
    Suwantika, Auliya A.
    Zakiyah, Neily
    Azis, Vanji Ikhsan
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 25 - 34
  • [2] COST-EFFECTIVENESS OF TENOFOVIR/LAMIVUDINE/EFAVIRENZ VERSUS TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR FOR PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV IN NIGERIA
    Ndai, A.
    Guo, Y.
    Jiao, T.
    Aroza, R.
    Park, H.
    Shao, H.
    Vouri, S. M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S336 - S337
  • [3] The effect on HIV transmission and cost-effectiveness of programmes for female sex workers in East, Central, and Southern Africa: a modelling study
    Bansi-Matharu, Loveleen
    Revill, Paul
    Taramusi, Issac
    Steen, Richard
    Chabata, Sungai
    Busza, Joanna
    Mangenah, Collin
    Musemburi, Sithembile
    Machingura, Fortunate
    Desmond, Nicola
    Matambanadzo, Primrose
    Shahmanesh, Maryam
    Yekeye, Raymond
    Mugurungi, Owen
    Cowan, Frances M.
    Hargreaves, James R.
    Phillips, Andrew N.
    [J]. LANCET GLOBAL HEALTH, 2024, 12 (09): : e1436 - e1445
  • [4] COST-EFFECTIVENESS OF DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE IN HIV-1 TREATMENT NAIVE PATIENTS IN FRANCE
    Pialoux, G.
    Marcelin, A.
    Cawston, H.
    Guilmet, C.
    Laurisse, A.
    Finkielsztejn, L.
    Aubin, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A587 - A587
  • [5] Cost-effectiveness analysis and HIV prevention community planning
    Pinkerton, SD
    Holtgrave, DR
    Willingham, M
    Goldstein, E
    [J]. AIDS & PUBLIC POLICY JOURNAL, 1998, 13 (03) : 115 - 127
  • [6] Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
    Pialoux, Gilles
    Marcelin, Anne-Genevieve
    Cawston, Helene
    Guilmet, Caroline
    Finkielsztejn, Laurent
    Laurisse, Audrey
    Aubin, Celine
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) : 83 - 91
  • [7] Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States
    Butler, Karin
    Anderson, Sarah-Jane
    Hayward, Olivia
    Jacob, Ian
    Punekar, Yogesh Suresh
    Evitt, Lee Alexandra
    Oglesby, Alan
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (07): : 891 - 903
  • [8] The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
    Girouard, Michael P.
    Sax, Paul E.
    Parker, Robert A.
    Taiwo, Babafemi
    Freedberg, Kenneth A.
    Gulick, Roy M.
    Weinstein, Milton C.
    Paltiel, A. David
    Walensky, Rochelle P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 62 (06) : 784 - 791
  • [9] Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa
    Mokaya, Jolynne
    Burn, Edward A. O.
    Tamandjou, Cynthia Raissa
    Goedhals, Dominique
    Barnes, Eleanor J.
    Andersson, Monique
    Pinedo-Villanueva, Rafael
    Matthews, Philippa C.
    [J]. BMC PUBLIC HEALTH, 2019, 19 (1)
  • [10] Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa
    Jolynne Mokaya
    Edward A. O. Burn
    Cynthia Raissa Tamandjou
    Dominique Goedhals
    Eleanor J. Barnes
    Monique Andersson
    Rafael Pinedo-Villanueva
    Philippa C. Matthews
    [J]. BMC Public Health, 19